



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

IAXO-102

Cat. No.:	HY-125171
CAS No.:	1115270-63-7
Molecular Formula:	C ₃₅ H ₇₁ NO ₅
Molecular Weight:	585.94
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

Ethanol : 50 mg/mL (85.33 mM; Need ultrasonic)
 DMSO : 3.33 mg/mL (5.68 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.7067 mL	8.5333 mL	17.0666 mL
	5 mM		0.3413 mL	1.7067 mL	3.4133 mL
	10 mM		0.1707 mL	0.8533 mL	1.7067 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 0.83 mg/mL (1.42 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil
 Solubility: ≥ 0.83 mg/mL (1.42 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development^[1].

IC₅₀ & Target

TLR4

In Vitro

IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells^[1].
 IAXO-102 (10 μM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Human umbilical vein endothelial (HUVEC) cells
Concentration:	1-10 μ M
Incubation Time:	Pretreatment for 1 hour and then exposed to LPS (100 ng/mL) for additional 1 hour
Result:	Significantly inhibited LPS-stimulated MAPK/p65NF-KB phosphorylation.

In Vivo

IAXO-102 (3 mg/kg/day, s.c. for 28 days) significantly retards Angiotensin II induced increase in aortic diameter in mice^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-monthold ApoE ^{-/-} /C57Bl6 ^[1]
Dosage:	3 mg/kg/day
Administration:	S.C. for 28 days
Result:	Significantly retarded Angiotensin II-induced increase in aortic diameter.

CUSTOMER VALIDATION

- Redox Biol. 2023 May 3, 102721.
- Mol Med Rep. 2021 Dec;24(6):868.
- Cancer Chemother Pharmacol. 2022 Aug 12.
- University of Adelaide. School of Biomedicine. 2022 Aug.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Huggins C, et al. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development. Atherosclerosis. 2015 Oct;242(2):563-70.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA